Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

H 1PV

Next Previous
X
Search
Drug Profile

H 1PV

Alternative Names: H-1PV; ParvOryx; parvovirus H1; Parvovirus-anticancer-ParvOryx; Parvovirus-antitumour-ParvOryx

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator German Cancer Research Center; University of Heidelberg
  • Developer Oryx GmbH & Co; University of Heidelberg
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell membrane modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Glioblastoma
  • No development reported Ovarian cancer

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in Germany (Parenteral)
  • 11 Nov 2019 Preclinical trials in Ovarian cancer in Germany (Parenteral) before November 2019
  • 11 Nov 2019 Pharmacodynamics data from a preclinical study in Ovarian cancer released by Oryx GMBH

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top